Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap2.84B
Enterprise Value2.41B
TXG
(NASDAQ)10x Genomics, Inc.
$22.33-- (--)
Loading... - Market loading
10x Genomics (TXG) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)4.36
Forward Price/Sales4.14
Price/Book (mrq)3.52
Price/Tangible Book (mrq)3.84
Price/FCF (ttm)21.54
Price/OCF (ttm)20.60
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue3.75
EV/Earnings-55.40
EV/EBITDA36.28
EV/EBIT106.33
EV/FCF18.54
Stock Price
Current price, 52-week range, and moving averages
Current Price$22.33
1-Day Change3.86%
52-Week High$23.56
52-Week Low$6.78
52-Week Change154.33%
YTD Change32.67%
1-Year Change149.15%
50-Day MA$20.05
200-Day MA$15.77
Avg Volume (30 day)1.28M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding127.08M
Book Value per Share$6.27
Net Cash per Share$3.64
FCF per Share$1.02
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$21.00
Target Upside/Downside-5.96%
Analyst ConsensusHold
Analyst Count5
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin69.05%
EBITDA Margin (ttm)10.35%
EBIT Margin (ttm)3.53%
Operating Margin (ttm)-17.25%
Pretax Margin (ttm)-6.21%
Profit Margin (ttm)-6.77%
FCF Margin (ttm)20.24%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-5.47%
Return on Assets (ttm)-4.18%
Return on Invested Capital (ttm)4.41%
Return on Capital Employed (ttm)2.56%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue642.82M
Gross Profit443.88M
Operating Income-110.89M
Pretax Income-39.91M
Net Income-43.54M
EBITDA66.50M
EBIT22.69M
Diluted EPS$-0.34
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow136.05M
Capital Expenditures5.93M
Free Cash Flow130.12M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth5.25%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)1.04B
Cash & Securities (mrq)473.97M
Net Cash (mrq)462.98M
Net Cash per Share$3.64
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)84.36M
Working Capital (mrq)531.00M
Total Equity (mrq)796.33M
Book Value per Share$6.27
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)4.46
Quick Ratio (mrq)4.09
Debt/Equity (mrq)0.11
Debt/EBITDA (ttm)1.27
Debt/FCF (ttm)0.65
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-1.55%
FCF Yield4.64%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score6.13
Piotroski F-Score4/9
Frequently Asked Questions About 10x Genomics Statistics
What are the key financial metrics for TXG?
10x Genomics, Inc. (TXG) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is TXG's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether 10x Genomics is overvalued or undervalued.
How do I read TXG's profitability ratios?
10x Genomics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do TXG's debt ratios indicate?
The financial health section shows 10x Genomics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is TXG's dividend analysis?
The dividend section covers 10x Genomics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.